참고문헌
- Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2014;63(25 Pt B):2889-934. https://doi.org/10.1016/j.jacc.2013.11.002
- Mora S, Wenger NK, DeMicco DA, et al. Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the treating to new targets (TNT) study. Circulation 2012;125:1979-87. https://doi.org/10.1161/CIRCULATIONAHA.111.088591
- Lim S, Park YM, Sakuma I, Koh KK. How to control residual cardiovascular risk despite statin treatment: Focusing on HDL-cholesterol. Int J Cardiol 2013;166:8-14. https://doi.org/10.1016/j.ijcard.2012.03.127
- Koh KK. How to control residual risk during statin era? J Am Coll Cardiol 2015;66:1848. https://doi.org/10.1016/j.jacc.2015.07.072
- Mora S, Caulfield MP, Wohlgemuth J, et al. Atherogenic lipoprotein subfractions determined by ion mobility and first cardiovascular events after random allocation to high-intensity statin or placebo: the JUPITER trial. Circulation 2015;132:2220-9. https://doi.org/10.1161/CIRCULATIONAHA.115.016857
- Lee MH, Kim HC, Ahn SV, et al. Prevalence of dyslipidemia among Korean adults: Korea National Health and Nutrition Survey 1998-2005. Diabetes Metab J 2012;36:43-55. https://doi.org/10.4093/dmj.2012.36.1.43
- Kim K. Distribution of blood cholesterol profile in untreated Korean population. Korean Circ J 2015;45:108-9. https://doi.org/10.4070/kcj.2015.45.2.108
- Park JH, Lee MH, Shim JS, et al. Effects of age, sex, and menopausal status on blood cholesterol profile in the Korean population. Korean Circ J 2015;45:141-8. https://doi.org/10.4070/kcj.2015.45.2.141
- Ren J, Grundy SM, Liu J, et al. Long-term coronary heart disease risk associated with very-low-density lipoprotein cholesterol in Chinese: the results of a 15-Year Chinese Multi-Provincial Cohort Study (CMCS). Atherosclerosis 2010;211:327-32. https://doi.org/10.1016/j.atherosclerosis.2010.02.020
- Lim S, Shin H, Song JH, et al. Increasing prevalence of metabolic syndrome in Korea: the Korean National Health and Nutrition Examination Survey for 1998-2007. Diabetes Care 2011;34:1323-8. https://doi.org/10.2337/dc10-2109
- Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet 2014;384:626-35. https://doi.org/10.1016/S0140-6736(14)61177-6
- Nordestgaard BG, Wootton R, Lewis B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler Thromb Vasc Biol 1995;15:534-42. https://doi.org/10.1161/01.ATV.15.4.534
- Goldberg IJ, Eckel RH, McPherson R. Triglycerides and heart disease: still a hypothesis? Arterioscler Thromb Vasc Biol 2011;31:1716-25. https://doi.org/10.1161/ATVBAHA.111.226100
- Proctor SD, Vine DF, Mamo JC. Arterial retention of apolipoprotein B(48)- and B(100)-containing lipoproteins in atherogenesis. Curr Opin Lipidol 2002;13:461-70. https://doi.org/10.1097/00041433-200210000-00001
- Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011;32:1345-61. https://doi.org/10.1093/eurheartj/ehr112
- Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013;61:427-36. https://doi.org/10.1016/j.jacc.2012.08.1026
- Hegele RA, Ginsberg HN, Chapman MJ, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2014;2:655-66. https://doi.org/10.1016/S2213-8587(13)70191-8
- Rapp JH, Lespine A, Hamilton RL, et al. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb 1994;14:1767-74. https://doi.org/10.1161/01.ATV.14.11.1767
- Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol 1997;17:715-22. https://doi.org/10.1161/01.ATV.17.4.715
- Zheng XY, Liu L. Remnant-like lipoprotein particles impair endothelial function: direct and indirect effects on nitric oxide synthase. J Lipid Res 2007;48:1673-80. https://doi.org/10.1194/jlr.R700001-JLR200
- Alipour A, van Oostrom AJ, Izraeljan A, et al. Leukocyte activation by triglyceride-rich lipoproteins. Arterioscler Thromb Vasc Biol 2008;28:792-7. https://doi.org/10.1161/ATVBAHA.107.159749
- Wang L, Gill R, Pedersen TL, Higgins LJ, Newman JW, Rutledge JC. Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation. J Lipid Res 2009;50:204-13. https://doi.org/10.1194/jlr.M700505-JLR200
- Moyer MP, Tracy RP, Tracy PB, van't Veer Cvt, Sparks CE, Mann KG. Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. Arterioscler Thromb Vasc Biol 1998;18:458-65. https://doi.org/10.1161/01.ATV.18.3.458
- Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000;342:1792-801. https://doi.org/10.1056/NEJM200006153422406
- Patel A, Barzi F, Jamrozik K, et al. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific Region. Circulation 2004;110:2678-86. https://doi.org/10.1161/01.CIR.0000145615.33955.83
- Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease 10,158 incident cases among 262,525 participants in 29 western prospective studies. Circulation 2007;115:450-8. https://doi.org/10.1161/CIRCULATIONAHA.106.637793
- Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;298:299-308. https://doi.org/10.1001/jama.298.3.299
- Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007;298:309-16. https://doi.org/10.1001/jama.298.3.309
- Langsted A, Freiberg J, Tybjaerg-Hansen A, Schnohr P, Jensen GB, Nordestgaard B. Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up. J Intern Med 2011;270:65-75. https://doi.org/10.1111/j.1365-2796.2010.02333.x
- Jorgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjaerg-Hansen A. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J 2013;34:1826-33. https://doi.org/10.1093/eurheartj/ehs431
- Emerging Risk Factors Collaboration, Di Angelantoni E, Sarwar N, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000. https://doi.org/10.1001/jama.2009.1619
- Rosenson RS, Davidson MH, Hirsh BJ, Kathiresan S, Gaudet D. Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. J Am Coll Cardiol 2014;64:2525-40. https://doi.org/10.1016/j.jacc.2014.09.042
- Schwartz GG, Abt M, Bao W, et al. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol 2015;65:2267-75. https://doi.org/10.1016/j.jacc.2015.03.544
- Jackson KG, Poppitt SD, Minihane AM. Postprandial lipemia and cardiovascular disease risk: interrelationships between dietary, physiological and genetic determinants. Atherosclerosis 2012;220:22-33. https://doi.org/10.1016/j.atherosclerosis.2011.08.012
- Rip J, Nierman MC, Ross CJ, et al. Lipoprotein lipase S447X a naturally occurring gain-of-function mutation. Arterioscler Thromb Vasc Biol 2006;26:1236-45. https://doi.org/10.1161/01.ATV.0000219283.10832.43
- Humphries SE, Nicaud V, Margalef J, Tiret L, Talmud PJ. Lipoprotein lipase gene variation is associated with a paternal history of premature coronary artery disease and fasting and postprandial plasma triglycerides: the European Atherosclerosis Research Study (EARS). Arterioscler Thromb Vasc Biol 1998;18:526-34. https://doi.org/10.1161/01.ATV.18.4.526
- Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation 1999;99:2901-7. https://doi.org/10.1161/01.CIR.99.22.2901
- Henderson HE, Kastelein JJ, Zwinderman AH, et al. Lipoprotein lipase activity is decreased in a large cohort of patients with coronary artery disease and is associated with changes in lipids and lipoproteins. J Lipid Res 1999;40:735-43.
- Lettre G, Palmer CD, Young T, et al. Genome-wide association study of coronary heart disease and its risk factors in 8,090 African Americans: the NHLBI CARe project. PLoS Genet 2011;7:e1001300. https://doi.org/10.1371/journal.pgen.1001300
- Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010;466:707-13. https://doi.org/10.1038/nature09270
- Waterworth DM, Ricketts SL, Song K, et al. Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arterioscler Thromb Vasc Biol 2010;30:2264-76. https://doi.org/10.1161/ATVBAHA.109.201020
- Do R, Willer CJ, Schmidt EM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet 2013;45:1345-52. https://doi.org/10.1038/ng.2795
- Khetarpal SA, Rader DJ. Triglyceride-rich lipoproteins and coronary artery disease risk: new insights from human genetics. Arterioscler Thromb Vasc Biol 2015;35:e3-9. https://doi.org/10.1161/ATVBAHA.114.305172
- Ooi EM, Barrett PH, Chan DC, Watts GF. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci (Lond) 2008;114:611-24. https://doi.org/10.1042/CS20070308
- Gaudet D, Alexander VJ, Baker BF, et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med 2015;373:438-47. https://doi.org/10.1056/NEJMoa1400283
- Kawakami A, Osaka M, Tani M, et al. Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction. Circulation 2008;118:731-42. https://doi.org/10.1161/CIRCULATIONAHA.108.784785
- Abe Y, Kawakami A, Osaka M, et al. Apolipoprotein CIII induces monocyte chemoattractant protein-1 and interleukin 6 expression via Toll-like receptor 2 pathway in mouse adipocytes. Arterioscler Thromb Vasc Biol 2010;30:2242-8. https://doi.org/10.1161/ATVBAHA.110.210427
- Qamar A, Khetarpal SA, Khera AV, Qasim A, Rader DJ, Reilly MP. Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics. Arterioscler Thromb Vasc Biol 2015;35:1880-8. https://doi.org/10.1161/ATVBAHA.115.305415
- TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute, Crosby J, Peloso GM, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 2014;371:22-31. https://doi.org/10.1056/NEJMoa1307095
- Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 2014;371:32-41. https://doi.org/10.1056/NEJMoa1308027
- Pennacchio LA, Olivier M, Hubacek JA, et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001;294:169-73. https://doi.org/10.1126/science.1064852
- Tang Y, Sun P, Guo D, et al. A genetic variant c.553G > T in the apolipoprotein A5 gene is associated with an increased risk of coronary artery disease and altered triglyceride levels in a Chinese population. Atherosclerosis 2006;185:433-7. https://doi.org/10.1016/j.atherosclerosis.2005.06.026
- Johansen CT, Wang J, Lanktree MB, et al. Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet 2010;42:684-7. https://doi.org/10.1038/ng.628
- Soufi M, Sattler AM, Kurt B, Schaefer JR. Mutation screening of the APOA5 gene in subjects with coronary artery disease. J Investig Med 2012;60:1015-9. https://doi.org/10.2310/JIM.0b013e3182686918
- Do R, Stitziel NO, Won HH, et al. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature 2015;518:102-6. https://doi.org/10.1038/nature13917
- Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors collaboration, Sarwar N, Sandhu MS, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010;375:1634-39. https://doi.org/10.1016/S0140-6736(10)60545-4
- Han SH, Quon MJ, Koh KK. Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators. Hypertension 2005;46:1086-92. https://doi.org/10.1161/01.HYP.0000187900.36455.4c
- Han SH, Oh PC, Lim S, Eckel RH, Koh KK. Comparative cardiometabolic effects of fibrates and omega-3 fatty acids. Int J Cardiol 2013;167:2404-11. https://doi.org/10.1016/j.ijcard.2013.01.223
- Koh KK, Ahn JY, Han SH, et al. Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis. Atherosclerosis 2004;174:379-83. https://doi.org/10.1016/j.atherosclerosis.2004.01.033
- Koh KK, Han SH, Quon MJ, Ahn JY, Shin EK. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 2005;28:1419-24. https://doi.org/10.2337/diacare.28.6.1419
- Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010;375:1875-84. https://doi.org/10.1016/S0140-6736(10)60656-3
- Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med 2010;363:692-4; author reply 694-5. https://doi.org/10.1056/NEJMc1006407
- Taher TH, Dzavik V, Reteff EM, Pearson GJ, Woloschuk BL, Francis GA. Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events. Am J Cardiol 2002;89:390-4. https://doi.org/10.1016/S0002-9149(01)02258-5
- Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 2005;45:1649-53. https://doi.org/10.1016/j.jacc.2005.02.052
- ACCORD Study Group, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74. https://doi.org/10.1056/NEJMoa1001282
- Koh KK, Quon MJ, Shin KC, et al. Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia. Atherosclerosis 2012;220:537-44. https://doi.org/10.1016/j.atherosclerosis.2011.11.018
- Kromhout D, Giltay EJ, Geleijnse JM; Alpha Omega Trial Group. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010;363:2015-26. https://doi.org/10.1056/NEJMoa1003603
- Kwak SM, Myung SK, Lee YJ, Seo HG; Korean Meta-analysis Study Group. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med 2012;172:686-94. https://doi.org/10.1001/archinternmed.2012.262
- Kaushik M, Mozaffarian D, Spiegelman D, Manson JE, Willett WC, Hu FB. Long-chain omega-3 fatty acids, fish intake, and the risk of type 2 diabetes mellitus. Am J Clin Nutr 2009:90:613-20. https://doi.org/10.3945/ajcn.2008.27424
- Djousse L, Gaziano JM, Buring JE, Lee IM. Dietary omega-3 fatty acids and fish consumption and risk of type 2 diabetes. Am J Clin Nutr 2011;93:143-50. https://doi.org/10.3945/ajcn.110.005603
- Oh PC, Koh KK, Sakuma I, et al. Omega-3 fatty acid therapy dosedependently and significantly decreased triglycerides and improved flow-mediated dilation, however, did not significantly improve insulin sensitivity in patients with hypertriglyceridemia. Int J Cardiol 2014;176:696-702. https://doi.org/10.1016/j.ijcard.2014.07.075
- Rischio and Prevenzione Investigators. Efficacy of n-3 polyunsaturated fatty acids and feasibility of optimizing preventive strategies in patients at high cardiovascular risk: rationale, design and baseline characteristics of the Rischio and Prevenzione study, a large randomised trial in general practice. Trials 2010;11:68. https://doi.org/10.1186/1745-6215-11-68
- Manson JE, Bassuk SS, Lee IM, et al. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials 2012;33:159-71. https://doi.org/10.1016/j.cct.2011.09.009
- Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther 2010;126:314-45. https://doi.org/10.1016/j.pharmthera.2010.01.008
- Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81. https://doi.org/10.1001/jama.1975.03240160024021
- Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55. https://doi.org/10.1016/S0735-1097(86)80293-5
- HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, et al. Effects of extended-release niacin with laropiprant in high risk patients. N Engl J Med 2014;371:203-12. https://doi.org/10.1056/NEJMoa1300955
- Crouse JR 3rd. Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. Am J Med 1987;83:243-8. https://doi.org/10.1016/0002-9343(87)90692-9
- Chapman MJ, Le Goff W, Guerin M, Kontush A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J 2010;31:149-64. https://doi.org/10.1093/eurheartj/ehp399
- Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22. https://doi.org/10.1056/NEJMoa0706628
- Schwartz GC, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. New Engl J Med 2012;367:2089-99. https://doi.org/10.1056/NEJMoa1206797
- Nicholls SJ, Lincoff AM, Barter PJ, et al. Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: rationale and design of the ACCELERATE trial. Am Heart J 2015;170:1061-9. https://doi.org/10.1016/j.ahj.2015.09.007
- Korstanje R, Eriksson P, Samnegard A, et al. Locating Ath8, a locus for murine atherosclerosis susceptibility and testing several of its candidate genes in mice and humans. Atherosclerosis 2004;177:443-50. https://doi.org/10.1016/j.atherosclerosis.2004.08.006
- Hatsuda S, Shoji T, Shinohara K, et al. Association between plasma angiopoietin-like protein 3 and arterial wall thickness in healthy subjects. J Vasc Res 2007;44:61-6. https://doi.org/10.1159/000098153
- Talmud PJ, Smart M, Presswood E, et al. ANGPTL4 E40K and T266M: effects on plasma triglyceride and HDL levels, postprandial responses, and CHD risk. Arterioscler Thromb Vasc Biol 2008;28:2319-25. https://doi.org/10.1161/ATVBAHA.108.176917
- Sacks FM, Stanesa M, Hegele RA. Severe hypertriglyceridemia with pancreatitis: thirteen years' treatment with lomitapide. JAMA Intern Med 2014;174:443-7. https://doi.org/10.1001/jamainternmed.2013.13309
피인용 문헌
- Structural design approaches for creating fat droplet and starch granule mimetics vol.8, pp.2, 2016, https://doi.org/10.1039/c6fo00764c
- Best Treatment Strategies With Statins to Maximize the Cardiometabolic Benefits vol.82, pp.4, 2016, https://doi.org/10.1253/circj.cj-17-1445
- Strategies to Overcome Residual Risk During Statins Era vol.83, pp.10, 2016, https://doi.org/10.1253/circj.cj-19-0624
- Chronic Sucrose Consumption Adversely Altered Antioxidant Status, Lipid Profile and Peroxidation of Rats Testes vol.19, pp.5, 2016, https://doi.org/10.3923/jbs.2019.354.362
- Identification of hypertriglyceridemia based on bone density, body fat mass, and anthropometry in a Korean population vol.19, pp.None, 2019, https://doi.org/10.1186/s12872-019-1050-2
- Short-Term Efficacy (at 12 Weeks) and Long-Term Safety (up to 52 Weeks) of Omega-3 Free Fatty Acids (AZD0585) for the Treatment of Japanese Patients With Dyslipidemia ― A Randomized, Double-Blind, Pl vol.84, pp.6, 2016, https://doi.org/10.1253/circj.cj-19-0358
- Lipoprotein(a) and Cardiovascular Diseases ― Revisited ― vol.84, pp.6, 2016, https://doi.org/10.1253/circj.cj-20-0051
- Cathepsin B Is Implicated in Triglyceride (TG)-Induced Cell Death of Macrophage vol.52, pp.3, 2016, https://doi.org/10.15324/kjcls.2020.52.3.245
- Design and rationale of a randomized control trial testing the effectiveness of combined therapy with STAtin plus FENOfibrate and statin alone in non-diabetic, combined dyslipidemia patients with non- vol.21, pp.1, 2016, https://doi.org/10.1186/s13063-020-04291-5
- New Trends in Dyslipidemia Treatment vol.85, pp.6, 2021, https://doi.org/10.1253/circj.cj-20-1037
- Genome-Wide Identification of Rare and Common Variants Driving Triglyceride Levels in a Nevada Population vol.12, pp.None, 2016, https://doi.org/10.3389/fgene.2021.639418
- Prospective Analysis of Lipid Variations in Hyperthyroid Subjects from Lahore, Pakistan vol.2021, pp.None, 2021, https://doi.org/10.1155/2021/9936782
- Consumption of Sourdough Breads Improves Postprandial Glucose Response and Produces Sourdough-Specific Effects on Biochemical and Inflammatory Parameters and Mineral Absorption vol.69, pp.10, 2016, https://doi.org/10.1021/acs.jafc.0c07200